Nona Biosciences’ Post

Technical review of ADCs for cancer therapies, including a brief discussion of the basics of ADCs, regulatory approach, overview, and technical complexities for quantification. The article summarizes recently approved ADCs and introduces the concepts of antibodies, linkers, and pay-loads. It also outlines cancer-specific ADCs currently in late-stage clinical trials for cancer treatment

Dr. Joe Abdo, II, Vice President of Clinical Diagnostics at OBD and a two-time cancer survivor, sheds light on the potential of #immunotherapy, its challenges, and the revolutionary EpiSwitch® CiRT blood test with Here to Serve, Inc. Learn more about it in our latest #InTheLoop blog post and empower yourself with knowledge that can transform the way we approach cancer immunotherapy treatment. Join us in revolutionizing #precisionmedicine! Click here: mycirt.co/here-to-serve.

During a recent presentation, Dr. Mohammad Abdolahad discussed the innovative cancer diagnostic probe (CDP) device and its successful verifications. This groundbreaking technology has the potential to revolutionize cancer diagnosis by providing an accurate method for detecting cancer cells in the body. Dr. Abdolahad detailed the various stages of development and testing that the CDP has undergone, highlighting its high sensitivity and specificity in detecting cancer cells. With promising results from clinical trials, this device holds great promise for improving cancer diagnosis and treatment outcomes. #cancersurvivor #breastcancer #breastcancerawareness #cancer #breastcancerawarenessmonth #cancertreatment #breast #diagnostic #surgical #surgery #surgicaloncology

I'm thrilled to share that our latest review article on "Cancer Immunotherapy and Vaccine" has been published. This comprehensive review discusses the topics of cancer immunotherapy and explores the clinical evidence and clinical applications of immunotherapy drugs as treatment in cancer management. Key highlights include: -The growing importance of mAbs and targeted therapy in cancer patients. -The efficacy and safety of CAR-T cell therapy in treating Blood cancer -Future directions for research and clinical applications Read the full article here: https://lnkd.in/gjE-nPks #cancer #immunotherapy #cancervaccines #car #mAbs #targetedtherapy #helia #Chimericantigenreceptors

Understand optimal intratumoral immunotherapy trial design with Society for Immunotherapy of Cancer (SITC)’s latest manuscript, “Society for Immunotherapy of Cancer recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease”. Published in the Journal for ImmunoTherapy of Cancer this manuscript provides guidance on how to design trials with the greatest likelihood of demonstrating the benefits of intratumoral immunotherapy across all stages of pathogenesis, and ultimately bring more effective treatment options to patients. View manuscript: https://ow.ly/6Knk50Rtx7I

This #BladderCancerAwarenessMonth let’s shine a light on immunotherapy offering hope to patients. The JAVELIN study presented by Powles et al. underscores the efficacy of our EpiSwitch® platform in predicting survival benefit for bladder cancer patients (#ESMO22). Notably, Keytruda, Opdivo, and Bavencio have all received FDA approval as immunotherapies for #bladdercancer. CiRT plays a pivotal role in identifying responders to these medications, a crucial step given the current lack of readily available biomarkers and molecular profiling for this cancer type. As we shift the paradigm of novel diagnostic innovation, let's raise awareness about the transformative potential of #immunotherapy in reshaping the landscape of bladder cancer treatment. #BladderCancerAwareness

If true, it might be a breakthrough. Still more data is needed, but look at this: In a retrospective analysis of patients with advanced lung cancer, 57.2% of people who happened to get Moderna or Pfizer-BioNTech’s shot within 100 days of starting treatment with a checkpoint inhibitor were still alive three years later, compared with 30.7% of patients who hadn’t recently gotten the Covid shot. The researchers said they found similarly encouraging results for 750 patients with metastatic melanoma treated with checkpoint inhibitors. After 3 years, 68.4% of patients who recently got the Covid shot were still alive, compared to 45.6% of patients who didn’t #esmo #clinicalresearch

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.